Form 4: Director Frissora Receives BDPT Convertible Stock

BIOADAPTIVES, INC. director Mark P. Frissora received 2,025 shares of Series D Convertible Preferred Stock as compensation for board services.

Summary

• Mark P. Frissora, a director of BIOADAPTIVES, INC. (BDPT), acquired 2,025 shares of Series D Convertible Preferred Stock on December 1, 2025.
• These shares were issued as compensation for board services, pursuant to a Board of Directors Agreement dated February 3, 2025.
• Each share of Series D Convertible Preferred Stock is convertible into 100 shares of common stock, implying a potential 202,500 common shares from this specific transaction.
• Conversion is subject to a 4.9% beneficial ownership limitation and cannot occur until six months after issuance (June 1, 2026), except in the case of liquidation.
• Each Series D Convertible Preferred Stock share carries 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation.
• Following this transaction, Mr. Frissora beneficially owns a total of 54,931 shares of Series D Convertible Preferred Stock.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. This is a routine compensation filing, indicating continued director involvement and alignment of interests through equity. The potential for future dilution is a minor negative, but expected with equity compensation and is subject to limitations.

Positives

• Issuance of convertible preferred stock as compensation aligns the director's interests with long-term shareholder value.
• The director's continued service and equity-based compensation indicate ongoing commitment to the company's strategic direction.
• The significant voting rights (100 votes per preferred share) provide the director with substantial influence on company matters, potentially contributing to stable governance.

Negatives

• Potential future dilution for common shareholders if the Series D Convertible Preferred Stock is converted into common stock.
• The 4.9% beneficial ownership limitation on conversion could restrict the director's immediate ability to fully convert all shares, potentially impacting liquidity for the director.

Risks

• Dilution Risk: Future conversion of Series D Convertible Preferred Stock into common stock could dilute the ownership percentage and earnings per share for existing common shareholders.
• Market Price Volatility: The value of the convertible preferred stock and its underlying common stock is subject to market fluctuations, which could impact the ultimate value of the compensation.

Future Outlook

The filing indicates continued board service by Mark P. Frissora, compensated with equity, suggesting ongoing involvement in the company's strategic direction. The non-expiring conversion rights provide long-term equity upside potential for the director.

Industry Context

This Form 4 filing represents a routine insider transaction for director compensation, a common practice across various industries. It reflects standard corporate governance where equity-based compensation is used to align the interests of directors with those of shareholders, incentivizing long-term performance and commitment.

Comparison to Industry Standards

• Compensating directors with equity, such as convertible preferred stock, is a widely accepted practice across industries to foster alignment between management and shareholder interests.
• The specific terms, including a 100:1 conversion ratio, a 4.9% beneficial ownership limitation, and 100 votes per preferred share, are specific to BIOADAPTIVES, INC. and would require detailed comparison with compensation structures of similar-stage companies or those with complex capital structures to assess their competitiveness or uniqueness. No specific comparable companies or projects are mentioned in the filing.

Corporate Governance

Related Party Transactions

• The acquisition of Series D Convertible Preferred Stock by Mark P. Frissora, a director, as compensation for board services, constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Potential for future dilution of common stock upon conversion of preferred shares. The director's increased equity stake may align interests with long-term shareholder value.
• Management: The equity compensation structure incentivizes the director's continued strategic input and oversight, potentially benefiting overall company governance.

Next Steps

• Monitoring future Form 4 filings for additional insider transactions by Mark P. Frissora or other company insiders.
• Observing any potential conversion of Series D Convertible Preferred Stock into common stock by the reporting person after the six-month restriction period.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation for an existing director. While it indicates continued commitment and aligns the director's interests with shareholders, it does not present new information that would fundamentally alter the investment thesis for BIOADAPTIVES, INC. The potential for future dilution is a known aspect of equity compensation and is subject to beneficial ownership limitations. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while monitoring future developments.

Keywords

BIOADAPTIVES, BDPT, Form 4, Insider Transaction, Convertible Preferred Stock, Director Compensation, Equity Compensation, Mark P. Frissora, Corporate Governance, Beneficial Ownership